What's in Maxinovel Pty., Ltd.'s pipeline?

Maxinovel Pty., Ltd. has 4 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 1 in Phase 1.

Which companies overlap with Maxinovel Pty., Ltd.'s portfolio?

Top competitors by shared drug class: ASLAN Pharmaceuticals, ATGC Co., Ltd., Addpharma Inc., Ahn-Gook Pharmaceuticals Co.,Ltd, Akeso.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/maxinovel-pty-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Maxinovel Pty., Ltd. — Portfolio Competitive Intelligence Brief

Maxinovel Pty., Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
"MAX-40279-01" and "Toripalimab"	"MAX-40279-01" and "Toripalimab"	marketed	PD-1 inhibitor	PD-1	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ASLAN Pharmaceuticals · 1 shared drug class
ATGC Co., Ltd. · 1 shared drug class
Addpharma Inc. · 1 shared drug class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
Akeso · 1 shared drug class
Amgen · 1 shared drug class
Asahi Kasei Pharma Corporation · 1 shared drug class
3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Maxinovel Pty., Ltd.:

Cite this brief

Drug Landscape (2026). Maxinovel Pty., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/maxinovel-pty-ltd. Accessed 2026-05-16.